These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29437873)

  • 1. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
    Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
    Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
    Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF
    Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
    Mittapalli RK; Vaidhyanathan S; Dudek AZ; Elmquist WF
    J Pharmacol Exp Ther; 2013 Mar; 344(3):655-64. PubMed ID: 23249624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.
    Vaidhyanathan S; Wilken-Resman B; Ma DJ; Parrish KE; Mittapalli RK; Carlson BL; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2016 Feb; 356(2):251-9. PubMed ID: 26604245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
    Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
    Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
    Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
    Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T; Agarwal S; Elmquist WF
    J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
    de Gooijer MC; Zhang P; Weijer R; Buil LCM; Beijnen JH; van Tellingen O
    Int J Cancer; 2018 Jan; 142(2):381-391. PubMed ID: 28921565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.
    Gampa G; Kim M; Mohammad AS; Parrish KE; Mladek AC; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2019 Mar; 368(3):446-461. PubMed ID: 30622172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
    Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
    Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.